PERIDEX ORAL RINSE Rx
Generic Name and Formulations:
Chlorhexidine gluconate 0.12%; contains alcohol 11.6%.
Indications for PERIDEX ORAL RINSE:
≥18yrs: Start after dental prophylaxis. Rinse with 15mL (undiluted) twice daily (AM & PM) for 30 seconds after brushing teeth; expectorate. Do not rinse with water or other mouthwashes, brush teeth, or eat immediately after use.
<18yrs: not recommended.
Do dental prophylaxis (calculus removal) before starting, then every 6 months. Coexisting gingivitis and periodontitis (effect on periodontitis not known, may cause increased supra- or subgingival calculus). May stain rough surfaces or margins of anterior facial restorations. Pregnancy (Category B). Nursing mothers.
Staining of teeth and other oral surfaces, increase in calculus formation, taste alteration, irritation or changes to oral mucosa (eg, stomatitis, dry mouth, ulceration).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML